654. Multiple Myeloma: Pharmacologic Therapies: Poster III

Belantamab mafodotin (belamaf) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for patients (pts) with transplant-ineligible (TI) newly diagnosed multiple myeloma (NDMM)

MagnetisMM 6 part 2 A phase 3 open label randomized study of elranatamab in combination with daratumumab and lenalidomide vs daratumumab lenalidomide and dexamethasone in transplant ineligible or deferred patients with newly diagnosed multiple myeloma

Surzetoclax ABBV 453 in combination with daratumumab and dexamethasone in biomarker selected patients with Relapsed Refractory multiple myeloma A Phase 1 2 multicenter open label platform study

Updated results from the frailty stratified randomised controlled bayesian adaptive trial of bortezomib versus lenalidomide in transplant ineligible myeloma TI NDMM – the FRAIL m study AMaRC 19 01 ALLG MM22

An immune therapeutic salvage strategy for ‘functional high risk FHR multiple myeloma MM incorporating iberdomide isatuximab and dexamethasone – the IBIS study amarc 20 01

Real world efficacy and safety of teclistamab in relapsed or refractory multiple myeloma Results from 87 patients treated by the polish myeloma group

A novel conditioning regimen combining selinexor with melphalan  Improves Survival in Patients with multiple myeloma a prospective study

First results of the rwe prospective study TEC care IFM 2023 01 evaluating teclistamab in triple class exposed relapsed refractory multiple myeloma patients

Phase I II study of mezigdomide and elranatamab for relapsed refractory multiple myeloma patients MELT MM Initial results from part 1

Final results of a multi center phase 2 trial of isatuximab lenalidomide in patients with high risk smoldering multiple myeloma HRSMM

Real world outcomes of elranatamab in relapsed refreactor multiple myeloma A single center analysis

Phase II trial of belantamab mafodotin carfilzomib pomalidomide and dexamethasone in multiple myeloma following BCMA CAR T cell therapy

QLS4131 a next generation GPRC5D×BCMA×CD3 trispecific T cell engager in patients with relapsed refractory multiple myeloma RRMM Initial results of a first in human Phase Ⅰa study

Renal response of selinexor   bortezomib pomalidomide and dexamethasone in newly diagnosed multiple myeloma patients with renal impairment A phase 2 prospective multicenter study

Safety and efficacy of first line selinexor plus bortezomib lenalidomide and dexamethasone XVRd in high risk newly diagnosed multiple myeloma A multi center single arm phase ib II trial

Efficacy and safety of daratumumab plus carfilzomib based induction consolidation maintenance therapy with autologous stem cell transplantation in transplant eligible ultra high risk newly diagnosed multiple myeloma Preliminary results

Talquetamab outcomes from practice outside of clinical trials The bital study

Isatuximab subcutaneous in relapsed refractory multiple myeloma Exposure response and serum m protein dynamics analyses from phase 3 iraklia Study and the phase 1b Study

Cancer selective targeting of the NF κB pathway via GADD45β MKK7 inhibition Results from the phase I trial of the first in class inhibitor DTP3 in patients with relapsed or refractory multiple myeloma

Deepening responses and MRD conversion in a phase II fixed duration consolidation trial of elranatamab post idecabtagene vicleucel CAR T cell therapy EPIC in relapsed or refractory multiple myeloma

Patient reported outcomes from dreamm 7 and dreamm 8 using the EQ 5D 3L patient global impression of severity and patient global impression of change

Utility and sensitivity of wett SA53 to measure dysgeusia associated with talquetamab a GPRC5D×CD3 bispecific antibody in Relapsed Refractory multiple myeloma Preliminary data from the talisman study

Functional high risk Relapsed Refractory multiple myeloma RRMM outcomes with belantamab mafodotin belamaf Dreamm 7 and dreamm 8 subgroup analysis

Isatuximab Isa subcutaneous SC via an on body injector OBI vs isa intravenous IV plus pomalidomide and dexamethasone Pd in relapsed refractory multiple myeloma RRMM East asia subgroup results from the randomized non inferiority phase 3 iraklia study

Updated survival outcomes of pomalidomide bortezomib dexamethasone in newly diagnosed multiple myeloma with renal impairment A prospective open label multicenter phase 2 study

Teclistamab in a large cohort of 100 Asian patients with triple class exposed multiple myeloma Experience from trials and non trial settings

Ultra sensitive detection of clonal m protein by mass spectrometry enhances detection of residual disease Results from A phase 1 study of etentamig monotherapy in patients with relapsed or refractory multiple myeloma

Isatuximab subcutaneous by on body injector in Relapsed Refractory multiple myeloma in the Phase 3 iraklia study Effect of body weight on pharmacokinetics and clinical outcome

Bortezomib bendamustine melphalan or high dose melphalan in autologous hematopoietic stem cell transplantation for previously transplanted relapsed multiple myeloma – a single center retrospective cohort study

Iberdomide plus daratumumab and dexamethasone IberDd in patients with newly diagnosed multiple myeloma by renal function A subgroup analysis of the CC 220 MM 001 trial

Kpg 818 a novel cereblon CRBN modulator in patients with hematological malignancies Results of a Phase 1 open label multiple ascending dose study

All trans retinoic acid and RARβ agonists enhance the efficacy of IMiD based treatments for t 4 14 multiple myeloma

Ultra sensitive detection of clonal m protein by mass spectrometry enhances detection of residual disease Results from A phase 1 study of etentamig monotherapy in patients with relapsed or refractory multiple myeloma

Isatuximab subcutaneous by on body injector in Relapsed Refractory multiple myeloma in the Phase 3 iraklia study Effect of body weight on pharmacokinetics and clinical outcome

Bortezomib bendamustine melphalan or high dose melphalan in autologous hematopoietic stem cell transplantation for previously transplanted relapsed multiple myeloma – a single center retrospective cohort study

Iberdomide plus daratumumab and dexamethasone IberDd in patients with newly diagnosed multiple myeloma by renal function A subgroup analysis of the CC 220 MM 001 trial

Kpg 818 a novel cereblon CRBN modulator in patients with hematological malignancies Results of a Phase 1 open label multiple ascending dose study

All trans retinoic acid and RARβ agonists enhance the efficacy of IMiD based treatments for t 4 14 multiple myeloma